Cancer Cachexia Market: High Prevalence in Advanced Cancers, New GDF-15 and Ghrelin-Targeted Therapies, and Multimodal Nutrition and Supportive Care to Drive Steady Market Expansion Through 2036

The global Cancer Cachexia Market was valued at USD 2,751.8 million in 2025 and is projected to expand at a steady CAGR of 5.3% to reach approximately USD 4,612.1 million by 2036, driven by the high prevalence of cachexia among patients with advanced pancreatic, gastric, lung, and other cancers, a growing pipeline of targeted therapies such as Pfizer’s GDF-15 antibody ponsegromab, now in a Phase 3 trial in pancreatic cancer, wider use of anamorelin and appetite stimulants, and greater emphasis on nutrition, exercise, and supportive care in oncology. The market encompasses cancer cachexia treatments by treatment type, drug class, cancer type, route of administration, end user, and distribution channel. Cachexia affects a large share of patients with advanced cancer and is linked to reduced treatment tolerance, shorter survival, and poorer quality of life.

The Cancer Cachexia Market’s steady 5.3% CAGR reflects growing recognition of cachexia as a serious and under-treated complication of cancer. Cachexia is a syndrome of involuntary weight loss and muscle wasting that cannot be fully reversed by conventional nutrition, and it reduces quality of life, tolerance of cancer treatment, and survival. With IARC estimating about 20 million new cancer cases a year, the number of patients at risk is large. New drugs targeting the biology of cachexia, such as GDF-15, have generated clinical interest after Pfizer reported weight gain in a Phase 2 study at ESMO 2024. Commercial interest has increased as large pharmaceutical companies invest in late-stage trials, and as cancer care increasingly focuses on quality of life and function alongside survival. Diagnosis remains inconsistent, as weight loss is often accepted as an unavoidable part of cancer, and many patients do not receive structured nutritional or medical treatment. Growing recognition among oncologists, combined with new clinical evidence, is expected to change this pattern over the forecast period.

Executive Snapshot

What is cancer cachexia?
Cancer cachexia is a complex syndrome of weight loss, muscle wasting, loss of appetite, and fatigue caused by tumor-driven inflammation and metabolic changes. It is especially common in pancreatic, gastric, esophageal, lung, and head and neck cancers. Unlike simple starvation, cachexia cannot be fully reversed by eating more, which is why targeted treatments are needed. Cachexia is often defined by weight loss of more than 5% over six months, along with other criteria. Cachexia is a syndrome of weight loss, muscle wasting, and loss of appetite.

Why is cachexia important for cancer outcomes?
Patients with cachexia tolerate chemotherapy and other treatments less well, have more complications, and often have shorter survival. Loss of muscle reduces physical function and independence. Treating cachexia may help patients stay on cancer therapy and maintain quality of life. Patients often describe cachexia as one of the most distressing aspects of advanced cancer. It reduces tolerance to chemotherapy and lowers survival.

What new therapies are in development?
Pfizer’s ponsegromab is an antibody that blocks GDF-15, a protein linked to appetite loss and weight loss. In a Phase 2 study presented at ESMO 2024, patients gained weight compared with placebo, and Pfizer has started a Phase 3 study in metastatic pancreatic cancer. Other companies are studying GDF-15 pathway drugs, ghrelin agonists, anti-inflammatory agents, and anabolic agents. Researchers are also studying combinations of drugs with nutrition and exercise. GDF-15 antibodies, ghrelin agonists, and other agents are in trials.

What treatments are available today?
Current options include appetite stimulants such as progestins and corticosteroids, the ghrelin receptor agonist anamorelin, which is approved in Japan, nutritional supplements and dietary counselling, and exercise programmes. Guidelines recommend multimodal care combining nutrition, exercise, symptom management, and medications where appropriate. Approved options vary by country, and many treatments are used off-label. Anamorelin is approved in Japan, while progestins and steroids are used elsewhere.

How do nutrition and supportive care fit in?
Dietitians assess nutritional needs and recommend high-calorie, high-protein supplements and oral nutrition. Enteral and parenteral nutrition are used in some patients. Exercise helps preserve muscle. Supportive care teams address pain, nausea, and depression that worsen appetite. Early nutritional assessment is recommended for patients at high risk. Dietary counselling, supplements, and exercise are recommended.

Which cancer types are most affected?
Pancreatic cancer has one of the highest cachexia rates, followed by gastric, esophageal, lung, colorectal, and head and neck cancers. Clinical trials often focus on pancreatic and lung cancer patients because of the high prevalence and need. Lung cancer patients often experience significant muscle loss. Pancreatic, gastric, lung, and colorectal cancers have high rates.

Who treats cachexia?
Oncologists, palliative care specialists, dietitians, and supportive care teams in hospitals, cancer centers, and specialty clinics manage cachexia. Home care and long-term care facilities support patients with advanced disease. Multidisciplinary teams improve recognition and management. Oncologists, dietitians, and palliative care teams treat patients.

How are treatments distributed?
Hospital pharmacies supply drugs for inpatients and infusion centers, while retail and specialty pharmacies supply oral drugs and nutritional supplements. Online pharmacies are growing for supplements and oral therapies. Specialty pharmacies may handle new targeted drugs once approved. Hospital and retail pharmacies distribute treatments.

What challenges face the market?
There are no widely approved cachexia-specific drugs in the United States or Europe, and past drug candidates have failed in late-stage trials. Defining clinical endpoints, such as weight and function, has been difficult. Awareness and screening for cachexia remain limited in routine care. Reimbursement for nutritional products varies by country. Lack of approved drugs and diagnosis gaps are challenges.

Which cancer cachexia market segments are growing fastest?
GDF-15 pathway inhibitors in development; ghrelin receptor agonists; nutritional and multimodal care programmes; pancreatic and lung cancer applications; and specialty and hospital pharmacy channels are the fastest-growing segments. Biomarkers such as GDF-15 levels may help select patients for treatment. Targeted therapies such as GDF-15 inhibitors are expected to be the fastest-growing segment if approved.

Market Dynamics: Cancer Cachexia Market

  • High unmet need: Most patients with cachexia have no approved targeted therapy. This creates a large opportunity. Patients and clinicians want better options.
  • Pipeline momentum: GDF-15 inhibitors such as ponsegromab are in Phase 3 trials. Positive results could transform care. GDF-15 has strong biological rationale.
  • Nutrition as the foundation: Supplements and dietary counselling are widely used. They support all treatment approaches. Nutritional products are widely available.
  • Japan leading approvals: Anamorelin is approved in Japan. Other regions await new approvals. Real-world data from Japan inform others.
  • Growing awareness: Oncology guidelines highlight cachexia screening. Clinicians are paying more attention. Screening tools are being introduced.
  • Trial design challenges: Endpoints such as weight and function are complex. Regulators and sponsors are refining approaches. Better endpoints could speed approvals.
  • Biomarker-driven approaches: GDF-15 levels may guide treatment. Biomarkers could improve trial success.
  • Combination strategies: Drugs combined with nutrition and exercise are being studied. Multimodal care is the standard approach.
  • Biomarkers: GDF-15 levels may help identify patients for treatment.
  • Exercise interventions: Resistance exercise helps preserve muscle mass.
  • Regulatory pathways: Regulators are discussing appropriate trial endpoints.

Market Segmentation: Cancer Cachexia Market

By Treatment Type
  • Appetite Stimulants
  • Cannabinoid Receptor Agonists
  • Corticosteroids
  • Anabolic and Androgenic Agents
  • Anti-Inflammatory Agents
  • Metabolic and Muscle-Preserving Agents
  • Other Treatments
By Treatment Mechanism
  • Appetite Stimulation
  • Inflammation Modulation
  • Muscle Mass Preservation
  • Anabolic Stimulation
  • Metabolic Regulation
  • Hormonal Modulation
  • Other Mechanisms
By Underlying Cancer Type
  • Lung Cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Small Cell Lung Cancer (SCLC)
  • Gastrointestinal Cancers
    • Pancreatic Cancer
    • Gastric Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Liver Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Head and Neck Cancer
  • Other Cancers
By Stage
  • Pre-Cachexia
  • Cachexia
  • Refractory Cachexia
By Route of Administration
  • Oral
  • Injectable
    • Intravenous
    • Intramuscular
    • Subcutaneous
  • Transdermal
  • Others
By End User
  • Hospitals
    • Oncology Departments
    • Cancer Specialty Hospitals
    • General Hospitals
  • Specialty Cancer and Oncology Clinics
  • Ambulatory Care Centers
  • Home Healthcare Settings
  • Other Healthcare Facilities
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Cancer Cachexia Market

  1. Rising cancer incidence: About 20 million new cancer cases occur each year. More patients live with advanced cancer. More cancer cases mean more patients.
  2. Advances in biology: Discovery of GDF-15 and other targets enables new drugs. GDF-15 is a validated target. New targets have been identified.
  3. Patient-centered oncology: Quality of life is a growing priority. Oncologists focus more on function and wellbeing. Quality of life is a priority.
  4. Multimodal care models: Combined nutrition, exercise, and drugs improve results. Guidelines support combined approaches. Combined care improves outcomes.
  5. Ageing populations: Older cancer patients are at greater risk of muscle loss. Sarcopenia is common in older patients. Older patients are more affected.
  6. Investment by pharmaceutical companies: Large companies are funding late-stage trials. Late-stage trials signal commitment. Investment supports trials.
  7. Palliative care growth: Expanding palliative services improve cachexia recognition. More patients receive supportive care.
  8. Clinical trial activity: More trials are underway for cachexia. Results will shape future treatment.
  9. Clinical trial progress: Late-stage trials are generating new evidence.

Regional Outlook: Cancer Cachexia Market

  • North America: The United States has active cachexia research and clinical trials, including Phase 3 studies of new agents. Supportive care and nutrition are widely used, but no cachexia-specific drug is approved. Patient advocacy groups raise awareness of cachexia. Large cancer centers run cachexia clinics. Patient advocacy groups are raising awareness of cachexia among clinicians.
  • Europe: European guidelines recommend multimodal cachexia care. Research centers in Germany, the UK, Italy, and the Nordic countries lead clinical studies. European researchers have led cachexia definition efforts. UK and Nordic centers study exercise interventions. Clinical guidelines from European oncology societies recommend early nutritional assessment.
  • Asia-Pacific: Japan has approved anamorelin for cancer cachexia, making it a leading market. China and South Korea have large numbers of gastric and lung cancer patients at risk. Japan’s approval of anamorelin offers real-world experience. China has large numbers of gastric cancer patients. Japan has the most experience with an approved cachexia drug.
  • Middle East & Africa: Access to supportive oncology care is improving in Gulf countries, while resources are limited in much of Africa. Palliative care services are expanding in the Gulf. Supportive care access is improving in Turkey. Access to supportive care varies widely across the region.

Competitive Landscape: Cancer Cachexia Market

Key Players: Pfizer, Ono Pharmaceutical, Helsinn, Novartis, Eli Lilly, AstraZeneca, Nestlé Health Science, Abbott Nutrition, Danone (Nutricia), Fresenius Kabi, Viatris, NGM Biopharmaceuticals, Aeterna Zentaris

Consultant POV

The Cancer Cachexia Market’s steady 5.3% CAGR from USD 2,751.8 million in 2025 toward approximately USD 4,612.1 million by 2036 is anchored in the large unmet need, new targeted drugs, and multimodal supportive care. Companies such as Pfizer, Ono Pharmaceutical, and Helsinn are developing and supplying therapies. Over the forecast period, approval of targeted drugs would be a major growth catalyst. Positive Phase 3 data for GDF-15 inhibitors would be a turning point, creating the first widely approved targeted treatment. Integration of cachexia screening into routine oncology care will be important for treatment uptake. Approval of a first targeted therapy in the United States or Europe would be a turning point, creating a defined treatment pathway and encouraging wider screening in oncology clinics. Collaboration between oncologists, dietitians, and palliative care teams, supported by validated screening tools and reimbursement for multimodal care, will be needed to translate scientific progress into better outcomes for patients.

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

Speak with an Analyst

    Download TOC